Efficacy of Alzer<sup>®</sup>and Diamel, Nutritional Supplements, in the Prevention of Severe Diabetic Macular Edema

• 作者: Eduardo Cabrera Rode Eduardo Sanz Navares Juan Lence Anta Juana Elvira Maciques Rodríguez Laura Rosa Redondo Piño Manuel Licea Puig Maria Emoé Pérez Muñoz Raísa Beltrán Sainz Rosaralis Paneca Santiesteban Teresa González Calero Yordanka Marrero Álvarez
• 来源期刊: 眼科学期刊(英文)
• 学科: 医学
• 关键词: Alzer Diamel Ginkgo Biloba Macular Edema Macular Thickness Nutritional Supplement
• 年，卷（期）: 2020,（4）
• 页码范围: 307-322
• 页数: 16页
• 分类号: R73

摘要

<b><span style="font-size:12px;font-family:Verdana;">Introduction: </span></b><span style="font-size:11.0pt;font-family:;" "=""><span style="font-family:Verdana;font-size:12px;">Macular edema is the main cause of low vision in diabetic patients. Laser photocoagulation continues to be the treatment of choice in conjunction with the use of steroids and anti-angiogenics, but these treatments include possible ocular complications. The nutritional supplement Alzer (whose primary active ingredient is </span><i><span style="font-family:Verdana;font-size:12px;">Ginkgo biloba</span></i><span style="font-family:Verdana;font-size:12px;">, a powerful antioxidant that acts on vascular factors and oxidative damage, which are two of the mechanisms implicated in the pathogenesis of diabetic macular edema), which has been used on other non-diabetic macular conditions, along with the Diamel nutritional supplement has been shown to be effective on glycemic control and could represent a treatment alternative for mild to moderate macular edema by reducing the thickness of the macular retina and preventing the progression of other more advanced clinical presentations that are harder to treat. </span><b><span style="font-family:Verdana;font-size:12px;">Objective: </span></b><span style="font-family:Verdana;font-size:12px;">Identify the effect of Alzer along with Diamel in reduction of the thickness of the macular retina among patients with mild to moderate diabetic macular edema. </span><b><span style="font-family:Verdana;font-size:12px;">Materials and Methods:</span></b><span style="font-family:Verdana;font-size:12px;"> A phase II double-blind clinical trial was conducted in 64 patients with non-severe diabetic macular edema over the course of non-proliferative diabetic retinopathy, who attended the ophthalmology service of the Institute of Endocrinology of Havana from January 2016 to December 2016. The treatment was randomly assigned to two groups: one received Alzer plus Diamel (n</span></span><span style="font-size:11.0pt;font-fami